혈우병 A 및 B : 세계 의약품 예측과 시장 분석(-2030년)

※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문목차를 참고해주시기 바랍니다.

유전자 치료제 4종, 모노클로널 항체 3종, 보충인자 2종, 효소 1종, 안티센스 올리고뉴클레오티드 1종의 합계 11종의 약제가 예측 기간 중 발매될 예정입니다. 시장 성장은 유전자 치료제의 발매, 예방적 치료에 대한 지속적 관심, 혈우병 환자의 평균수명 상승에 의해 촉진될 전망입니다. 그러나 시장의 성장을 방해하는 주요 요인으로 유전자 치료의 높은 초기 비용에 의한 시장 참여 문제 및 특정 국가에서 환자 수의 감소 등을 들 수 있습니다.

세계의 혈우병 A 및 B 시장에 대해 조사분석했으며, 질병의 개요, 역학, 미충족 요구와 기회 평가, 연구개발 전략 등의 정보를 정리하여 전해드립니다.

목차

목차

제1장 혈우병 A 및 B : 개요

• 2030년까지 147억 1,000만 달러로 성장할 것으로 예상되는 혈우병 A 및 B 시장
• 응고 캐스케이드의 유전자 치료와 대체 모듈레이터가 계속 주요 연구개발 초점
• 다양한 환자층에서 혁신적인 약제의 미충족 요구에 일부 대응하나 치료비는 증가 동향
• 혈우병 A 및 B의 후기 파이프라인을 지배하는 유전자 치료
• 의사의 견해

제2장 서론

제3장 질병의 개요

• 병인과 병태생리학
  • 병인
  • 병태생리학

제4장 역학

• 질병 배경
• 위험인자와 병존 질환
• 세계 및 과거의 동향
• 8MM 예측 조사 방법
  • 정보원
  • 사용되지 않은 정보원
  • 예측의 전제조건과 방법
  • 혈우병 A 및 B의 진단된 유병률
  • 혈우병 A 및 B의 진단된 유병률 : 중증도별
  • 혈우병 A 및 B의 진단된 유병률 : 저해제 상태별
  • 혈우병 A 및 B의 진단된 유병률의 저해제간 중증도
  • 혈우병 A 및 B의 진단된 유병률의 치료 유형
  • 후천성 혈우병의 진단된 유병률
• 혈우병 A의 역학적 예측(2020-2030년)
  • 혈우병 A의 진단된 유병률
  • 혈우병 A의 진단된 유병률 : 연령별
  • 혈우병 A의 진단된 유병률 : 성별
  • 혈우병 A의 진단된 유병률 : 중증도별
  • 저해제를 수반하는 혈우병 A의 진단된 유병률
• 혈우병 A 및 B의 역학적 예측(2020-2030년)
  • 혈우병 A 및 B의 진단된 유병률
  • 혈우병 A 및 B의 진단된 유병률 : 연령별
  • 혈우병 A 및 B의 진단된 유병률 : 성별
  • 혈우병 A 및 B의 진단된 유병률 : 중증도별
  • 저해제를 수반하는 혈우병 A 및 B의 진단된 유병률
  • 혈우병 A 및 B의 진단된 유병률의 저해제간 중증도
  • 혈우병 A 및 B의 진단된 유병률의 치료 유형
  • 후천성 혈우병의 진단된 유병률
• 토론
  • 역학 예측 인사이트
  • COVID-19의 영향
  • 분석의 한계
  • 분석의 강점

제5장 질병 관리

• 진단과 치료의 개요
  • 저해제 없는 혈우병 A 및 B
  • 혈우병 A 및 B와 저해제
• 질병 관리에 관한 KOL 인사이트
  • 저해제 없는 혈우병 A 및 B
  • 혈우병 A 및 B와 저해제

제6장 현재의 치료 옵션

• 개요

제7장 미충족 요구와 기회 평가

• 개요
• 보다 치유력 있는 치료법의 개발
• 이전 치료를 받지 않은 환자에 대한 저해제 개발의 리스크 저감
• 저해제를 사용한 혈우병 B 환자에 대한 효과적인 치료
• 예방에 관련된 비용의 삭감
• 편리한 관리 루트를 갖춘 보다 많은 치료법

제8장 연구개발 전략

제9장 파이프라인 평가

• 개요
• 임상 개발의 유망 약제

제10장 파이프라인 평가 분석

• 개요
• 경쟁 평가

제11장 현재 및 향후 기업

• 개요
• 거래의 동향

제12장 시장 전망

제13장 부록

List of Tables

List of Tables

• Table 1: Hemophilia A and B: Key Metrics in the 8MM
• Table 2: Severity Classifications of Hemophilia
• Table 3: Relationship of Bleeding Severity with Clotting Factor Level
• Table 4: Comorbidities for Hemophilia
• Table 5: Treatment Guidelines for Hemophilia A and B
• Table 6: Top 10 Deals by Value, 2017-2021
• Table 7: Hemophilia A and B Market - Global Drivers and Barriers, 2020-2030
• Table 8: Key Events Impacting Sales for Hemophilia A and B in the US, 2020-2030
• Table 9: Hemophilia A and B Market - Drivers and Barriers in the US, 2020-2030
• Table 10: Key Events Impacting Sales for Hemophilia A and B in the 5EU, 2020-2030
• Table 11: Hemophilia A and B Market - Drivers and Barriers in the 5EU, 2020-2030
• Table 12: Key Events Impacting Sales for Hemophilia A and B in Japan, 2020-2030
• Table 13: Hemophilia A and B Market - Drivers and Barriers in Japan, 2020-2030
• Table 14: Key Events Impacting Sales for Hemophilia A and B in China, 2020-2030
• Table 15: Hemophilia A and B Market - Drivers and Barriers in China, 2020-2030
• Table 16: High-Prescribing Physicians (non-KOLs) Surveyed, By Country

List of Figures

List of Figures

• Figure 1: Global Sales Forecast by Country for Hemophilia A and B in 2020 and 2030
• Figure 2: Analysis of the Company Portfolio Gap in Hemophilia A and B During the Forecast Period
• Figure 3: Competitive Assessment of the Late-Stage Pipeline Agents that GlobalData Expects to Be Licensed for the Treatment of Hemophilia A and B During the Forecast Period
• Figure 4: The Cascade of Events that Lead to the Formation of Blood Clots
• Figure 5: Common Areas of Bleeding and Classes of Therapy
• Figure 6: 8MM, Diagnosed Prevalence of Hemophilia A (%), Both Sexes, All Ages
• Figure 7: 8MM, Diagnosed Prevalence of Hemophilia B (%), Both Sexes, All Ages
• Figure 8: 8MM, Sources Used to Forecast the Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B
• Figure 9: 8MM, Sources Used to Forecast the Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B, by Severity
• Figure 10: 8MM, Sources Used to Forecast the Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B, by Inhibitors
• Figure 11: 8MM, Sources Used to Forecast the Severity Among Inhibitors in Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B
• Figure 12: 8MM, Sources Used to Forecast the Types of Treatment Among Hemophilia A and Hemophilia B Patients
• Figure 13: 8MM, Sources Used to Forecast the Diagnosed Prevalent Cases of Acquired Hemophilia
• Figure 14: 8MM, Diagnosed Prevalent Cases of Hemophilia A, N, Both Sexes, All Ages, 2020
• Figure 15: 8MM, Diagnosed Prevalent Cases of Hemophilia A by Age, N, Both Sexes
• Figure 16: 8MM, Diagnosed Prevalent Cases of Hemophilia A by Sex, N, All Ages, 2020
• Figure 17: 8MM, Diagnosed Prevalent Cases of Hemophilia A by Severity, N, Both Sexes, All Ages, 2020
• Figure 18: 8MM, Diagnosed Prevalent Cases of Hemophilia A with Inhibitors, N, Both Sexes, All Ages, 2020
• Figure 19: 8MM, Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B, N, Both Sexes, All Ages, 2020
• Figure 20: 8MM, Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B by Age, N, Both Sexes, 2020
• Figure 21: 8MM, Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B by Sex, N, All Ages, 2020
• Figure 22: 8MM, Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B by Severity, N, Both Sexes, All Ages, 2020
• Figure 23: 8MM, Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B with Inhibitors, N, Both Sexes, All Ages, 2020
• Figure 24: 8MM, Severity Among Inhibitors in Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B, Both Sexes, All Ages, N, 2020
• Figure 25: 8MM, Types of Treatment Among the Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B, Both Sexes, All Ages, N, 2020
• Figure 26: 8MM, Diagnosed Prevalent Cases of Acquired Hemophilia, N, Both Sexes, All Ages, 2020
• Figure 27: Treatment Algorithm for Hemophilia A and B
• Figure 28: Unmet Needs and Opportunities in Hemophilia A and B
• Figure 29: Overview of the Development Pipeline in Hemophilia A and B
• Figure 30: Key Late-Stage Trials for the Promising Pipeline Agents that GlobalData Expects to Be Licensed for Hemophilia A and B in the 8MM During the Forecast Period
• Figure 31: Competitive Assessment of the Marketed and Pipeline Drugs For Hemophilia A and B Benchmarked Against the SOC Class of Drugs, Recombinant Replacement Factor
• Figure 32: Competitive Assessment of the Marketed and Pipeline Drugs For Hemophilia A and B Benchmarked Against the SOC Class of Drugs, Alternative Coagulation Promoter
• Figure 33: Analysis of the Company Portfolio Gap in Hemophilia A and B During the Forecast Period
• Figure 34: Global (8MM) Sales Forecast by Country for Hemophilia A and B in 2020 and 2030
• Figure 35: Sales Forecast by Class for Hemophilia A and B in the US in 2020 and 2030
• Figure 36: Sales Forecast by Class for Hemophilia A and B in the 5EU in 2020 and 2030
• Figure 37: Sales Forecast by Class for Hemophilia A and B in Japan in 2020 and 2030
• Figure 38: Sales Forecast by Class for Hemophilia A and B in China in 2020 and 2030

Hemophilia A and B are rare disorders in coagulation, characterized by the failure of blood to form normal clots after damage to veins and tissue. The patient population is increasing as a result of longer life expectancies and an aging population. Hemophilia A and B is mostly treated with prophylactic recombinant replacement factor therapy. The current market leader is Roche's Hemlibra however, BioMarin's gene therapy Roctavian is expected to be the market leader at the end of the forecast period.

The global market is expected to experience growth during the forecast period. Eleven agents are forecast to launch in the forecast period in the 8MM; four gene therapies, three monoclonal antibodies, two replacement factors, one enzyme and one antisense oligonucleotide. Growth will be driven by the launch of gene therapies, continuing preference for prophylactic regiments, and an increasing life expectancy for hemophiliacs. The major barriers for growth in the hemophilia A and B market include the possible market access issues for gene therapies due to high upfront costs and declining prevalent cases in certain countries.

Key Highlights

• Growth will be driven by the launch of gene therapies, continuing preference for prophylactic regiments, and an increasing life expectancy for hemophiliacs
• The major barriers for growth in the hemophilia A and B market include the possible market access issues for gene therapies due to high upfront costs and declining prevalent cases in certain countries
• BioMarin's Roctavian is expected to leapfrog Hemlibra's sales to become the market leader by the end of the forecast period
• The most important unmet needs in the Hemophilia A and B market include: the development of more curative treatments, more therapies for hemophilia B patients with inhibitors, decreasing the costs of prophylactic treatment, and introducing more therapies with convenient routes of administration

KEY QUESTIONS ANSWERED

• 11 late-stage pipeline agents are expected to enter the Hemophilia A and B market from 2021 onwards. What impact will these agents have on the market?
• Which of these drugs will have the highest peak sales, and why?
• What are the current unmet needs in Hemophilia A and B, which pipeline agents are positioned to counter these unmet needs?
• What are the opportunities for R&D?
• What is the market outlook in the 8MM from 2020-2030? Considering major patent expiries, launch of new premium priced agents and expected label expansions.
• What are the main corporate trends?
• Who are the current and future players?

Scope

• Overview of Hemophilia A and B including epidemiology, pathophysiology, symptoms, diagnosis, and treatment guidelines.
• Topline Hemophilia A and B market revenue, annual cost of therapy, and major pipeline product sales in the forecast period.
• Key topics covered include current treatment and pipeline therapies, unmet needs and opportunities, and the drivers and barriers affecting Hemophilia A and B therapeutics sales in the 8MM.
• Pipeline analysis: Comprehensive data split across different phases, emerging novel trends under development, and detailed analysis of late-stage pipeline drugs (Phase II - III).
• Analysis of the current and future market competition in the global Hemophilia A and B therapeutics market. Insightful review of the key industry drivers and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to Buy

The report will enable you to -

• Develop and design your in-licensing and out-licensing strategies, using a detailed overview of current pipeline products and technologies to identify companies with the most robust pipelines.
• Develop business strategies by understanding the trends shaping and driving the global Hemophilia A and B therapeutics market.
• Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global Hemophilia A and B market in the future.
• Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
• Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
• Track drug sales in the global Hemophilia A and B therapeutics market from 2020-2030.
• Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

Table of Contents

Table of Contents

1 Hemophilia A and B: Executive Summary

• 1.1 The Hemophilia A and B Market Is Expected to Grow to $14.71B by 2030
• 1.2 Gene Therapies and Alternative Modulators of the Coagulation Cascade Remain the Main R&D Focus
• 1.3 Unmet Need for Innovative Agents in Different Patient Populations to be Partially Addressed but with Increasing Cost of Therapy
• 1.4 Gene Therapies to Dominate the Late-Stage Pipeline of Hemophilia A and B
• 1.5 What Do Physicians Think?

2 Introduction

• 2.1 Catalyst
• 2.2 Related Reports
• 2.3 Upcoming Reports

3 Disease Overview

• 3.1 Etiology and Pathophysiology
  • 3.1.1 Etiology
  • 3.1.2 Pathophysiology

4 Epidemiology

• 4.1 Disease Background
• 4.2 Risk Factors and Comorbidities
• 4.3 Global and Historical Trends
• 4.4 8MM Forecast Methodology
  • 4.4.1 Sources
  • 4.4.2 Sources Not Used
  • 4.4.3 Forecast Assumptions and Methods
  • 4.4.4 Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B
  • 4.4.5 Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B by Severity
  • 4.4.6 Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B by Inhibitor Status
  • 4.4.7 Severity Among Inhibitors in Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B
  • 4.4.8 Types of Treatment Among Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B
  • 4.4.9 Diagnosed Prevalent Cases of Acquired Hemophilia
• 4.5 Epidemiological Forecast for Hemophilia A (2020-2030)
  • 4.5.1 Diagnosed Prevalent Cases of Hemophilia A
  • 4.5.2 Age-Specific Diagnosed Prevalent Cases of Hemophilia A
  • 4.5.3 Sex-Specific Diagnosed Prevalent Cases of Hemophilia A
  • 4.5.4 Diagnosed Prevalent Cases of Hemophilia A by Severity
  • 4.5.5 Diagnosed Prevalent Cases of Hemophilia A with Inhibitors
• 4.6 Epidemiological Forecast for Hemophilia A and Hemophilia B (2020-2030)
  • 4.6.1 Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B
  • 4.6.2 Age-Specific Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B
  • 4.6.3 Sex-Specific Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B
  • 4.6.4 Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B by Severity
  • 4.6.5 Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B with Inhibitors
  • 4.6.6 Severity Among Inhibitors in Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B
  • 4.6.7 Types of Treatment Among the Diagnosed Prevalent Cases of Hemophilia A and Hemophilia B
  • 4.6.8 Diagnosed Prevalent Cases of Acquired Hemophilia
• 4.7 Discussion
  • 4.7.1 Epidemiological Forecast Insight
  • 4.7.2 COVID-19 Impact
  • 4.7.3 Limitations of the Analysis
  • 4.7.4 Strengths of the Analysis

5 Disease Management

• 5.1 Diagnosis and Treatment Overview
  • 5.1.1 Hemophilia A and B Without Inhibitors
  • 5.1.2 Hemophilia A and B with Inhibitors
• 5.2 KOL Insights on Disease Management
  • 5.2.1 Hemophilia A and B Without Inhibitors
  • 5.2.2 Hemophilia A and B with Inhibitors

6 Current Treatment Options

• 6.1 Overview

7 Unmet Needs and Opportunity Assessment

• 7.1 Overview
• 7.2 Development of More Curative Treatments
• 7.3 Reduction in Risk of Inhibitor Development in Previously Untreated Patients
• 7.4 More Effective Treatments for Hemophilia B Patients with Inhibitors
• 7.5 Decreasing the Costs Associated with Prophylaxis
• 7.6 More Therapies with Convenient Administration Routes

8 R&D Strategies

9 Pipeline Assessment

• 9.1 Overview
• 9.2 Promising Drugs in Clinical Development

10 Pipeline Valuation Analysis

• 10.1 Overview
• 10.2 Competitive Assessment

11 Current and Future Players

• 11.1 Overview
• 11.2 Deal-Making Trends

12 Market Outlook

13 Appendix